US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Conduit Pharmaceuticals Inc.

2.00

-0.1000-4.76%

Post-market: 2.100.0996+4.98%19:57 EDT

Volume:115.08K

Turnover:234.97K

Market Cap:4.81M

PE:-0.01

High:2.13

Open:2.10

Low:2.00

Close:2.10

Loading ...

Overview Company News Filings

Conduit Pharmaceuticals Inc - Secures Composition of Matter Patent From Uspto for Azd1656

THOMSON REUTERS

Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

Oxbridge / SurancePlus to Speak at Uncorrelated Puerto Rico on April 1st

Conduit Pharmaceuticals provides R&D upgrade on AZD1656, AZD5658, AZD5904

Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets Azd1656, Azd5658, and Azd5904

THOMSON REUTERS

Conduit Pharmaceuticals - Results for Study With Charles River Laboratories Expected in Q2 2025

THOMSON REUTERS

Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904

Is Conduit Pharmaceuticals Inc. (CDT) the Best Micro Cap Stock to Buy Now?

Conduit Pharmaceuticals Gets Nasdaq Extension, Plans Capital Market Transfer

MT Newswires Live

Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel

THOMSON REUTERS

BRIEF-Conduit Pharmaceuticals Files For Offering Of Up To $17.8 Million Of Shares Of Common Stock - SEC Filing

Conduit Pharmaceuticals Files for Offering of up to $17.8 Mln of Shares of Common Stock - SEC Filing

THOMSON REUTERS

Conduit Pharmaceuticals, Charles River Laboratories Partner to Evaluate Potential Lupus Treatment

MT Newswires Live

BRIEF-Conduit Pharmaceuticals Partners With Charles River In Systemic Lupus Erythematosus Model

Conduit Pharmaceuticals: Study to Accelerate Development of Azd1656 for Autoimmune Disorders, Focus on Systemic Lupus Erythematosus, Lupus Nephritis

THOMSON REUTERS

Conduit Pharmaceuticals Inc: Partners With Charles River in Clinically Relevant Systemic Lupus Erythematosus Model

THOMSON REUTERS

Conduit announces debt repayment, conversion of senior secured note

Conduit Pharmaceuticals Announces Debt Repayment and Partial Conversion of Senior Secured Note

THOMSON REUTERS

Press Release: Conduit Pharmaceuticals Announces Debt Repayment and Partial Conversion of Senior Secured Note

Conduit Pharmaceuticals Transitions to Phase Ii of Sarborg Collaboration to Support AI-Driven Drug Development

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CDT/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CDT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CDT\",,,,,undefined,":{"symbol":"CDT","market":"US","secType":"STK","nameCN":"Conduit Pharmaceuticals Inc.","latestPrice":2,"timestamp":1753473600000,"preClose":2.1,"halted":0,"volume":115077,"hourTrading":{"tag":"盘后","latestPrice":2.0996,"preClose":2,"latestTime":"19:57 EDT","volume":5643,"amount":11811.7915,"timestamp":1753487871120},"delay":0,"floatShares":2079613,"shares":2405100,"eps":-307.95898,"marketStatus":"Market Closed","change":-0.1,"latestTime":"07-25 16:00:00 EDT","open":2.1,"high":2.1342,"low":2,"amount":234972.734298,"amplitude":0.063905,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-307.95898,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1753689600000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":2.1,"preHourTrading":{"tag":"盘前","latestPrice":2.14,"preClose":2.1,"latestTime":"09:07 EDT","volume":765,"amount":1664.607105,"timestamp":1753448868464},"postHourTrading":{"tag":"盘后","latestPrice":2.0996,"preClose":2,"latestTime":"19:57 EDT","volume":5643,"amount":11811.7915,"timestamp":1753487871120},"volumeRatio":0.8868207068796168},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CDT\",,,,,undefined,":{"symbol":"CDT","floatShares":2079613,"roa":"-168.26%","roe":"--","lyrEps":-307.95897,"volumeRatio":0.8868207068796168,"shares":2405100,"dividePrice":0,"high":2.1342,"amplitude":0.063905,"preClose":2.1,"low":2,"week52Low":1.94,"pbRate":"1.79","week52High":622.5,"institutionHeld":0,"latestPrice":2,"eps":-307.95898,"divideRate":0,"volume":115077,"delay":0,"ttmEps":-307.95898,"open":2.1,"prevYearClose":102.9,"prevWeekClose":2.11,"prevMonthClose":2.76,"prevQuarterClose":2.76,"fiveDayClose":2.11,"twentyDayClose":2.51,"sixtyDayClose":8.4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CDT\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2523949510","title":"Conduit Pharmaceuticals Inc - Secures Composition of Matter Patent From Uspto for Azd1656","url":"https://stock-news.laohu8.com/highlight/detail?id=2523949510","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523949510?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:35","pubTimestamp":1743424507,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QE0VM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","CDT"],"gpt_icon":0},{"id":"2523941750","title":"Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2523941750","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523941750?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:30","pubTimestamp":1743424200,"startTime":"0","endTime":"0","summary":"Conduit secures a composition of matter patent from the USPTO for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnerships.NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 31, 2025  -- Conduit Pharmaceuticals Inc.   today announces that the United States Patent and Trademark Office  has granted the composition of matter patent for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune diseases, including Lupus and ANCA Vasculitis. With this critical composition of matter patent protection now secured, the Company is strategically positioned to advance AZD1656 into clinical development, with clinical trial plans now in final stages of preparation.Conduit is a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development. Conduit both acquires and funds the development of Phase 2-ready assets, building an integrated and adv","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/conduit-pharmaceuticals-receives-u-patent-123000741.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CDTTW","CDT"],"gpt_icon":0},{"id":"2521747413","title":"Oxbridge / SurancePlus to Speak at Uncorrelated Puerto Rico on April 1st","url":"https://stock-news.laohu8.com/highlight/detail?id=2521747413","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521747413?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:00","pubTimestamp":1742817600,"startTime":"0","endTime":"0","summary":"GRAND CAYMAN, Cayman Islands, March  24, 2025  (GLOBE NEWSWIRE) -- Oxbridge Re Holdings Limited (Nasdaq: OXBR) (“Oxbridge Re”), together with its subsidiary SurancePlus, is engaged in the tokenization","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/24/3047770/0/en/Oxbridge-SurancePlus-to-Speak-at-Uncorrelated-Puerto-Rico-on-April-1st.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OXBR","CDT","BK4019","BK4121"],"gpt_icon":0},{"id":"2520858184","title":"Conduit Pharmaceuticals provides R&D upgrade on AZD1656, AZD5658, AZD5904","url":"https://stock-news.laohu8.com/highlight/detail?id=2520858184","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520858184?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:37","pubTimestamp":1742387827,"startTime":"0","endTime":"0","summary":"Conduit Pharmaceuticals (CDT) provides an R&D update on the development progress of pipeline assets AZD1656, AZD5658, and AZD5904. The Company has ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/conduit-pharmaceuticals-provides-rd-upgrade-on-azd1656-azd5658-azd5904?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/conduit-pharmaceuticals-provides-rd-upgrade-on-azd1656-azd5658-azd5904?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","CDT"],"gpt_icon":0},{"id":"2520893691","title":"Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets Azd1656, Azd5658, and Azd5904","url":"https://stock-news.laohu8.com/highlight/detail?id=2520893691","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520893691?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:30","pubTimestamp":1742387401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nTUA2PXNRD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","CDT"],"gpt_icon":0},{"id":"2520892831","title":"Conduit Pharmaceuticals - Results for Study With Charles River Laboratories  Expected in Q2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2520892831","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520892831?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:30","pubTimestamp":1742387401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nTUA2PXNRD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4530","CDT","BK4588","BK4585","CRL","LU0390134368.USD","BK4121"],"gpt_icon":0},{"id":"2520181351","title":"Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904","url":"https://stock-news.laohu8.com/highlight/detail?id=2520181351","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520181351?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:30","pubTimestamp":1742387400,"startTime":"0","endTime":"0","summary":"Conduit Pharmaceuticals advances its pipeline with key progress in preclinical lupus studies for AZD5658, Phase IIa trial design for AZD1656, formulation optimization, and IP expansion, positioning the Company for near-term milestones and growth.At its research and development facility at Cambridge Science Park, Conduit is enhancing its IP portfolio and optimize the formulation of its pipeline assets. In the laboratory, the Company is evaluating the assets licensed through the AstraZeneca partnership and other assets of critical interest. Significant progress has also been made in securing intellectual property  protection for Conduit’s lead asset, AZD1656. Recent milestones include the grant of a composition-of-matter patent for the AZD1656 Cocrystals by the Japan Patent Office  and IP Australia, with pending applications at the USPTO and European Patent Office, and other global patent offices, expected to be approved early in the second quarter. In addition, Conduit is actively worki","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/conduit-pharmaceuticals-provides-research-development-123000754.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4121","CDT","LU1481599808.USD","SLE","BK4136","BK4097","IP","BK4585","BK4588","LU1487256676.USD","BK4077","LU2065732104.USD","PRGS","LU2463526074.USD","LU1481600234.SGD","CDTTW"],"gpt_icon":0},{"id":"2517102384","title":"Is Conduit Pharmaceuticals Inc. (CDT) the Best Micro Cap Stock to Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2517102384","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517102384?lang=en_us&edition=fundamental","pubTime":"2025-03-07 17:53","pubTimestamp":1741341217,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Best Micro Cap Stocks to Buy Now.In this article, we are going to take a look at where Conduit Pharmaceuticals Inc.  stands against the other micro cap stocks.Just as we overlook loose change, micro-cap stocks are often ignored for larger, more dominant enterprises. Investors trying to play safe ignore the fact that every strong stock was once a micro-cap stock. This niche segment of the market offers higher risk and, if successful, higher returns, particularly present in emerging industries where there is potential to outperform peers.Thus, with low price valuations by the investors, these stocks will continue to offer returns that surpass the returns from private equity fund investments. In view of this, we will take a look at some of the best","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/conduit-pharmaceuticals-inc-cdt-best-095337236.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CDTTW","NVIW.SI","QLD","SQQQ","MNQmain","BK4121","CDT",".IXIC","CDTDA","TQQQ","TSYW.SI","USAW.SI","USJW.SI","NQmain","QID","PSQ"],"gpt_icon":1},{"id":"2517164682","title":"Conduit Pharmaceuticals Gets Nasdaq Extension, Plans Capital Market Transfer","url":"https://stock-news.laohu8.com/highlight/detail?id=2517164682","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517164682?lang=en_us&edition=fundamental","pubTime":"2025-03-06 23:41","pubTimestamp":1741275704,"startTime":"0","endTime":"0","summary":"Conduit Pharmaceuticals  said Thursday that a Nasdaq hearing panel granted it an extension to meet listing requirements, with plans to transfer its shares to the Nasdaq Capital Market.The company said it must submit an application for the transfer by March 12 and meet all Nasdaq listing standards by March 31.Conduit said it had been at risk of delisting for not meeting requirements related to minimum bid price, market value of publicly held shares, and market value of listed securities. It regained compliance with the minimum bid price rule as of Feb. 26, according to the company.Following the transfer, the company expects to meet the continued listing requirement for publicly held shares above $1.0 million and believes it will satisfy the Nasdaq equity standard of stockholder's equity above $2.5 million before the March 31 deadline, though it cautioned that compliance is not assured.Shares of Conduit Pharmaceuticals were up nearly 4% in recent trading.Price: 1.11, Change: +0.04, Perce","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CDT.AU","CDT","TSYW.SI","BK7104","CDTDA","MNQmain","IE00B64PRP62.GBP","BK4121","LU2210150020.SGD","LU2210149790.SGD","QLD","QID","NDAQ","BK4112","IE00BGHQF748.EUR","TQQQ","NQmain","USAW.SI","IE00BKPKM429.USD","BK4588",".IXIC","USJW.SI","PSQ","IE00B3QW5Z07.USD","NVIW.SI","BK4585","LU2095319765.USD","SQQQ"],"gpt_icon":1},{"id":"2517316377","title":"Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel","url":"https://stock-news.laohu8.com/highlight/detail?id=2517316377","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517316377?lang=en_us&edition=fundamental","pubTime":"2025-03-06 22:35","pubTimestamp":1741271747,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nTUA619YD5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","CDT","CDTDA"],"gpt_icon":0},{"id":"2512866074","title":"BRIEF-Conduit Pharmaceuticals Files For Offering Of Up To $17.8 Million Of Shares Of Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2512866074","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512866074?lang=en_us&edition=fundamental","pubTime":"2025-02-19 23:25","pubTimestamp":1739978732,"startTime":"0","endTime":"0","summary":"BRIEF-Conduit Pharmaceuticals Files For Offering Of Up To $17.8 Million Of Shares Of Common Stock - SEC FilingFeb 19  - Conduit Pharmaceuticals Inc CDT.O:CONDUIT PHARMACEUTICALS FILES FOR OFFERING OF UP TO $17.8 MILLION OF SHARES OF COMMON STOCK - SEC FILINGSource text: [ID:n0001493152-25-007520]Further company coverage: CDT.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250219:nFWN3PA0J9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDT","BK4121"],"gpt_icon":0},{"id":"2512100818","title":"Conduit Pharmaceuticals Files for Offering of up to $17.8 Mln of Shares of Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2512100818","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512100818?lang=en_us&edition=fundamental","pubTime":"2025-02-19 22:06","pubTimestamp":1739973993,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250219:nFWN3PA0J9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","CDT"],"gpt_icon":0},{"id":"2511210845","title":"Conduit Pharmaceuticals, Charles River Laboratories Partner to Evaluate Potential Lupus Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2511210845","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511210845?lang=en_us&edition=fundamental","pubTime":"2025-02-13 23:35","pubTimestamp":1739460927,"startTime":"0","endTime":"0","summary":"Conduit Pharmaceuticals (CDT) said Thursday it partnered with Charles River Laboratories International (CRL) to evaluate its AZD1656 drug candidate and its derivatives in a preclinical model of system","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4121","BK4530","CRL.AU","CRL","CDT","CDT.AU","LU0390134368.USD","BK7104","BK7095","BK4588","BK4585"],"gpt_icon":0},{"id":"2511424585","title":"BRIEF-Conduit Pharmaceuticals Partners With Charles River In Systemic Lupus Erythematosus Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2511424585","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511424585?lang=en_us&edition=fundamental","pubTime":"2025-02-13 21:07","pubTimestamp":1739452050,"startTime":"0","endTime":"0","summary":"BRIEF-Conduit Pharmaceuticals Partners With Charles River In Systemic Lupus Erythematosus ModelFeb 13 (Reuters) - Conduit Pharmaceuticals CDT.O:CONDUIT PHARMACEUTICALS INC: PARTNERS WITH CHARLES RIVER","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250213:nFWN3P41F0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","CRL","BK4121","BK4530","CDT","LU0390134368.USD","BK4585"],"gpt_icon":0},{"id":"2511542663","title":"Conduit Pharmaceuticals: Study to Accelerate Development of Azd1656 for Autoimmune Disorders, Focus on Systemic Lupus Erythematosus, Lupus Nephritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2511542663","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511542663?lang=en_us&edition=fundamental","pubTime":"2025-02-13 21:01","pubTimestamp":1739451689,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250213:nFWN3P41F0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","LU0390134368.USD","BK4121","CDT","BK4588","CRL","BK4530"],"gpt_icon":0},{"id":"2511426935","title":"Conduit Pharmaceuticals Inc: Partners With Charles River in Clinically Relevant Systemic Lupus Erythematosus Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2511426935","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511426935?lang=en_us&edition=fundamental","pubTime":"2025-02-13 21:01","pubTimestamp":1739451689,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250213:nFWN3P41F0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CDT","BK4585","CRL","BK4530","BK4588","LU0390134368.USD","BK4121"],"gpt_icon":0},{"id":"2510384271","title":"Conduit announces debt repayment, conversion of senior secured note","url":"https://stock-news.laohu8.com/highlight/detail?id=2510384271","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510384271?lang=en_us&edition=fundamental","pubTime":"2025-02-11 22:11","pubTimestamp":1739283088,"startTime":"0","endTime":"0","summary":"Conduit Pharmaceuticals (CDT) announces the repayment of its $600,000 promissory note to Nirland and provided an update on the conversion of its Se...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/conduit-announces-debt-repayment-conversion-of-senior-secured-note?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/conduit-announces-debt-repayment-conversion-of-senior-secured-note?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CDT","BK4121"],"gpt_icon":0},{"id":"2510384827","title":"Conduit Pharmaceuticals Announces Debt Repayment and Partial Conversion of Senior Secured Note","url":"https://stock-news.laohu8.com/highlight/detail?id=2510384827","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510384827?lang=en_us&edition=fundamental","pubTime":"2025-02-11 22:00","pubTimestamp":1739282404,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nTUARWMT0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","CDT"],"gpt_icon":0},{"id":"2510479384","title":"Press Release: Conduit Pharmaceuticals Announces Debt Repayment and Partial Conversion of Senior Secured Note","url":"https://stock-news.laohu8.com/highlight/detail?id=2510479384","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510479384?lang=en_us&edition=fundamental","pubTime":"2025-02-11 22:00","pubTimestamp":1739282400,"startTime":"0","endTime":"0","summary":"NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 11, 2025  -- Conduit Pharmaceuticals Inc.  , today announces the repayment of its $600,000 promissory note  to Nirland Limited  and provided an update on the conversion of its Senior Secured Promissory Note  with Nirland. On February 7, 2025, Conduit repaid the final balance of the Note in full, satisfying all obligations under the agreement. The Note, issued on October 28, 2024, had an original principal amount of $600,000, bore interest at a rate of 12% per annum, and was due to mature on October 31, 2025.In addition, as of February 10, 2025, Nirland has converted approximately $1.7 million of the original $2.65 million principal amount under the Senior Note into shares of Conduit's common stock. The Senior Note, initially entered into on August 6, 2024, and subsequently amended in October and November 2024, bears interest at a rate of 12% per annum, accruing daily and payable monthly in arrears, either in cash or as accrued at Nirland","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","CDT"],"gpt_icon":1},{"id":"2509484357","title":"Conduit Pharmaceuticals Transitions to Phase Ii of Sarborg Collaboration to Support AI-Driven Drug Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2509484357","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509484357?lang=en_us&edition=fundamental","pubTime":"2025-02-07 21:00","pubTimestamp":1738933200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250207:nTUA6JP54K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CDT","BK4121"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":68,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CDT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-20","symbol":"CDT","defaultRemindTime":1747747800000,"type":"split","dateTimestamp":1747713600000,"forFactor":15,"toFactor":1,"ratio":15},{"market":"US","date":"2025-01-27","symbol":"CDT","defaultRemindTime":1737988200000,"type":"split","dateTimestamp":1737954000000,"forFactor":100,"toFactor":1,"ratio":100}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CDT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CDT\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CDT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CDT","date":"2025-07-24","current":-0.269084,"percent":0.775414,"low":-460.917103,"twenty":-44.134478,"median":-2.181695,"eighty":-0.25477,"high":-0.0799,"avg":-35.088686,"sd":83.894628,"marketCap":5219153},"quantilePoints":[{"date":"2023-10-13","current":-14.733381,"twenty":-17.829889,"median":-16.48141,"eighty":-15.432593,"marketCap":128180419},{"date":"2023-10-20","current":-14.483663,"twenty":-16.181748,"median":-14.691762,"eighty":-14.550255,"marketCap":126007869},{"date":"2023-10-27","current":-9.739015,"twenty":-15.882086,"median":-14.650142,"eighty":-14.017522,"marketCap":84729429},{"date":"2023-11-03","current":-12.652395,"twenty":-15.199522,"median":-14.483663,"eighty":-12.552508,"marketCap":110075840},{"date":"2023-11-10","current":-10.071973,"twenty":-14.799973,"median":-12.902114,"eighty":-10.821128,"marketCap":87626162},{"date":"2023-11-17","current":-9.745674,"twenty":-14.66679,"median":-12.152959,"eighty":-9.744342,"marketCap":84787364},{"date":"2023-11-24","current":-24.87973,"twenty":-14.683438,"median":-11.487043,"eighty":-9.941453,"marketCap":133977347},{"date":"2023-12-01","current":-63.281053,"twenty":-17.380396,"median":-12.694015,"eighty":-10.221804,"marketCap":340768471},{"date":"2023-12-08","current":-47.866438,"twenty":-32.992686,"median":-14.483663,"eighty":-10.372134,"marketCap":257760767},{"date":"2023-12-15","current":-96.544171,"twenty":-48.488431,"median":-14.650142,"eighty":-10.455207,"marketCap":519890360},{"date":"2023-12-22","current":-67.607963,"twenty":-67.878395,"median":-15.066339,"eighty":-10.588057,"marketCap":364068880},{"date":"2023-12-29","current":-66.255804,"twenty":-68.040654,"median":-16.106832,"eighty":-10.687945,"marketCap":356787502},{"date":"2024-01-05","current":-66.120588,"twenty":-67.716136,"median":-18.728875,"eighty":-10.787832,"marketCap":356059364},{"date":"2024-01-12","current":-60.576735,"twenty":-67.716136,"median":-27.854481,"eighty":-10.887719,"marketCap":326205716},{"date":"2024-01-19","current":-38.130891,"twenty":-67.526833,"median":-37.184379,"eighty":-11.204029,"marketCap":205334848},{"date":"2024-01-26","current":-38.942186,"twenty":-66.82371,"median":-38.942186,"eighty":-11.453747,"marketCap":209703674},{"date":"2024-02-02","current":-35.697004,"twenty":-66.30989,"median":-38.468931,"eighty":-11.886593,"marketCap":192228368},{"date":"2024-02-09","current":-43.742352,"twenty":-66.174674,"median":-38.266107,"eighty":-12.452621,"marketCap":235552565},{"date":"2024-02-16","current":-41.240857,"twenty":-65.71494,"median":-38.468931,"eighty":-12.702339,"marketCap":222082016},{"date":"2024-02-23","current":-38.266107,"twenty":-64.633212,"median":-38.468931,"eighty":-12.868818,"marketCap":206062986},{"date":"2024-03-01","current":-34.750493,"twenty":-63.362183,"median":-38.536539,"eighty":-13.634621,"marketCap":187131404},{"date":"2024-03-08","current":-35.83222,"twenty":-63.226967,"median":-38.198499,"eighty":-14.483663,"marketCap":192956506},{"date":"2024-03-15","current":-42.998664,"twenty":-62.118196,"median":-38.266107,"eighty":-14.550255,"marketCap":231547807},{"date":"2024-03-22","current":-46.649494,"twenty":-58.954144,"median":-38.80697,"eighty":-14.650142,"marketCap":251207527},{"date":"2024-03-28","current":-48.272085,"twenty":-56.303911,"median":-39.212618,"eighty":-14.66679,"marketCap":259945180},{"date":"2024-04-05","current":-44.215608,"twenty":-55.411486,"median":-39.753482,"eighty":-14.799973,"marketCap":238101047},{"date":"2024-04-12","current":-43.13388,"twenty":-54.194543,"median":-40.294346,"eighty":-15.199522,"marketCap":232275945},{"date":"2024-04-19","current":-40.993558,"twenty":-49.732418,"median":-40.835209,"eighty":-15.882086,"marketCap":220750312},{"date":"2024-04-26","current":-427.79731,"twenty":-59.765439,"median":-41.117207,"eighty":-16.930903,"marketCap":228871561},{"date":"2024-05-03","current":-412.617406,"twenty":-65.03886,"median":-41.781721,"eighty":-19.959046,"marketCap":220750312},{"date":"2024-05-10","current":-419.517363,"twenty":-67.256401,"median":-42.187369,"eighty":-24.87973,"marketCap":224441789},{"date":"2024-05-17","current":-89.879435,"twenty":-68.824906,"median":-42.728232,"eighty":-26.06963,"marketCap":217058835},{"date":"2024-05-24","current":-90.49086,"twenty":-78.722712,"median":-42.998664,"eighty":-31.234879,"marketCap":218535426},{"date":"2024-05-31","current":-91.713709,"twenty":-86.822311,"median":-42.998664,"eighty":-32.85747,"marketCap":221488608},{"date":"2024-06-07","current":-85.905174,"twenty":-88.962298,"median":-43.539528,"eighty":-34.750493,"marketCap":207460996},{"date":"2024-06-14","current":-61.753897,"twenty":-87.739448,"median":-43.80996,"eighty":-34.966839,"marketCap":149135662},{"date":"2024-06-21","current":-44.634005,"twenty":-87.066881,"median":-44.080392,"eighty":-35.264314,"marketCap":107791122},{"date":"2024-06-28","current":-31.182661,"twenty":-86.822311,"median":-44.080392,"eighty":-35.020925,"marketCap":75306126},{"date":"2024-07-05","current":-19.568648,"twenty":-86.822311,"median":-43.80996,"eighty":-32.160941,"marketCap":47258285},{"date":"2024-07-12","current":-8.865658,"twenty":-86.822311,"median":-43.336704,"eighty":-24.87973,"marketCap":21410565},{"date":"2024-07-15","current":-8.024949,"twenty":-86.822311,"median":-43.13388,"eighty":-24.87973,"marketCap":19380253},{"date":"2024-08-02","current":-6.267103,"twenty":-86.638884,"median":-43.066272,"eighty":-20.630864,"marketCap":15135054},{"date":"2024-08-09","current":-5.19711,"twenty":-85.477177,"median":-42.998664,"eighty":-16.282943,"marketCap":12551021},{"date":"2024-08-16","current":-2.669983,"twenty":-83.616666,"median":-42.79584,"eighty":-14.799973,"marketCap":15197543},{"date":"2024-08-23","current":-2.782989,"twenty":-82.833276,"median":-42.457801,"eighty":-14.483663,"marketCap":15840775},{"date":"2024-08-30","current":-2.194345,"twenty":-81.616333,"median":-41.849329,"eighty":-12.669043,"marketCap":12490211},{"date":"2024-09-06","current":-2.099892,"twenty":-79.777396,"median":-41.511289,"eighty":-11.403804,"marketCap":11952585},{"date":"2024-09-13","current":-2.329278,"twenty":-74.503975,"median":-40.970425,"eighty":-10.48817,"marketCap":13258248},{"date":"2024-09-20","current":-2.255065,"twenty":-70.177065,"median":-40.294346,"eighty":-9.745674,"marketCap":12835828},{"date":"2024-09-27","current":-2.172418,"twenty":-69.636202,"median":-39.888698,"eighty":-9.018515,"marketCap":12365405},{"date":"2024-10-04","current":-1.66136,"twenty":-68.960122,"median":-39.618266,"eighty":-8.024949,"marketCap":9456462},{"date":"2024-10-11","current":-1.72714,"twenty":-68.284042,"median":-38.942186,"eighty":-5.597593,"marketCap":9830881},{"date":"2024-10-18","current":-1.71196,"twenty":-68.148827,"median":-38.401323,"eighty":-2.782989,"marketCap":9744476},{"date":"2024-10-25","current":-2.062785,"twenty":-67.607963,"median":-38.130891,"eighty":-2.68685,"marketCap":11741374},{"date":"2024-10-31","current":-1.791696,"twenty":-67.49979,"median":-37.590027,"eighty":-2.642322,"marketCap":10198332},{"date":"2024-11-08","current":-1.699632,"twenty":-66.607365,"median":-37.522419,"eighty":-2.434525,"marketCap":9674307},{"date":"2024-11-15","current":-0.683034,"twenty":-66.282847,"median":-37.18438,"eighty":-2.341422,"marketCap":9657424},{"date":"2024-11-22","current":-0.732446,"twenty":-66.147631,"median":-36.711124,"eighty":-2.250005,"marketCap":11097296},{"date":"2024-11-29","current":-0.724301,"twenty":-65.88513,"median":-36.035044,"eighty":-2.191309,"marketCap":10973878},{"date":"2024-12-06","current":-0.642842,"twenty":-65.728158,"median":-35.697004,"eighty":-2.136324,"marketCap":9739703},{"date":"2024-12-13","current":-0.648697,"twenty":-65.557968,"median":-34.885709,"eighty":-2.104952,"marketCap":9828408},{"date":"2024-12-20","current":-0.518958,"twenty":-64.227565,"median":-32.405511,"eighty":-2.070881,"marketCap":7862726},{"date":"2024-12-27","current":-0.460417,"twenty":-63.362183,"median":-30.829231,"eighty":-1.971833,"marketCap":6975772},{"date":"2025-01-03","current":-0.598858,"twenty":-63.25401,"median":-24.87973,"eighty":-1.919522,"marketCap":9073299},{"date":"2025-01-10","current":-0.648697,"twenty":-63.145837,"median":-19.568648,"eighty":-1.895806,"marketCap":9828408},{"date":"2025-01-17","current":-0.583827,"twenty":-61.753897,"median":-17.605142,"eighty":-1.8334,"marketCap":8845567},{"date":"2025-01-24","current":-0.395547,"twenty":-60.812167,"median":-15.982791,"eighty":-1.791603,"marketCap":5992932},{"date":"2025-01-31","current":-0.201729,"twenty":-57.331553,"median":-15.066339,"eighty":-1.741555,"marketCap":3056394},{"date":"2025-02-07","current":-0.122619,"twenty":-55.654875,"median":-14.650142,"eighty":-1.697038,"marketCap":1857808},{"date":"2025-02-14","current":-0.128948,"twenty":-55.330356,"median":-14.483663,"eighty":-1.649553,"marketCap":1953695},{"date":"2025-02-21","current":-0.09414,"twenty":-55.13826,"median":-12.778777,"eighty":-0.882703,"marketCap":1426317},{"date":"2025-02-28","current":-0.088602,"twenty":-53.010523,"median":-12.402677,"eighty":-0.73059,"marketCap":1342416},{"date":"2025-03-07","current":-0.08702,"twenty":-50.521832,"median":-11.403804,"eighty":-0.711674,"marketCap":1318444},{"date":"2025-03-14","current":-0.0799,"twenty":-49.678331,"median":-10.737889,"eighty":-0.666568,"marketCap":1210571},{"date":"2025-03-21","current":-0.211359,"twenty":-49.502551,"median":-10.405763,"eighty":-0.647115,"marketCap":3202300},{"date":"2025-03-28","current":-0.184627,"twenty":-48.933528,"median":-9.908824,"eighty":-0.629809,"marketCap":2797277},{"date":"2025-04-04","current":-0.256525,"twenty":-48.406557,"median":-9.739015,"eighty":-0.621391,"marketCap":4566652},{"date":"2025-04-11","current":-0.400469,"twenty":-48.109826,"median":-8.942087,"eighty":-0.595694,"marketCap":7129147},{"date":"2025-04-17","current":-0.291968,"twenty":-47.947567,"median":-8.781761,"eighty":-0.581358,"marketCap":5197615},{"date":"2025-04-25","current":-0.344257,"twenty":-47.812352,"median":-6.267103,"eighty":-0.56231,"marketCap":6128471},{"date":"2025-05-02","current":-0.356677,"twenty":-47.623049,"median":-5.703064,"eighty":-0.504244,"marketCap":6349572},{"date":"2025-05-09","current":-0.25477,"twenty":-47.217401,"median":-5.19711,"eighty":-0.463265,"marketCap":4535409},{"date":"2025-05-16","current":-0.251612,"twenty":-46.771188,"median":-2.780459,"eighty":-0.362983,"marketCap":4880275},{"date":"2025-05-23","current":-0.168975,"twenty":-46.541321,"median":-2.718896,"eighty":-0.355913,"marketCap":3277441},{"date":"2025-05-30","current":-0.14883,"twenty":-46.352019,"median":-2.669983,"eighty":-0.34483,"marketCap":2886700},{"date":"2025-06-06","current":-0.111006,"twenty":-46.216803,"median":-2.62107,"eighty":-0.333579,"marketCap":2153063},{"date":"2025-06-13","current":-0.121263,"twenty":-45.946372,"median":-2.495396,"eighty":-0.294505,"marketCap":2352008},{"date":"2025-06-20","current":-0.116353,"twenty":-45.297335,"median":-2.403491,"eighty":-0.27026,"marketCap":2256785},{"date":"2025-06-27","current":-0.123226,"twenty":-45.162119,"median":-2.352891,"eighty":-0.260629,"marketCap":2390097},{"date":"2025-07-03","current":-0.143355,"twenty":-44.739628,"median":-2.304822,"eighty":-0.25477,"marketCap":2780511},{"date":"2025-07-11","current":-0.298844,"twenty":-44.623805,"median":-2.255065,"eighty":-0.252406,"marketCap":5796387},{"date":"2025-07-18","current":-0.276524,"twenty":-44.296737,"median":-2.193501,"eighty":-0.254337,"marketCap":5363462},{"date":"2025-07-24","current":-0.269084,"twenty":-44.134478,"median":-2.181695,"eighty":-0.25477,"marketCap":5219153}],"updateTime":1753515317730}}}